Seagen (Seagen) Change In Receivables : $-145 Mil (TTM As of Sep. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Seagen Change In Receivables?

Seagen's change in receivables for the quarter that ended in Sep. 2023 was $-46 Mil. It means Seagen's Accounts Receivable increased by $46 Mil from Jun. 2023 to Sep. 2023 .

Seagen's change in receivables for the fiscal year that ended in Dec. 2022 was $-113 Mil. It means Seagen's Accounts Receivable increased by $113 Mil from Dec. 2021 to Dec. 2022 .

Seagen's Accounts Receivable for the quarter that ended in Sep. 2023 was $632 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Seagen's Days Sales Outstanding for the three months ended in Sep. 2023 was 88.85.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Seagen's liquidation value for the three months ended in Sep. 2023 was $892 Mil.

Seagen Change In Receivables Historical Data

The historical data trend for Seagen's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seagen Change In Receivables Chart

Seagen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

-45.23

-89.72

-88.73

-64.27

-112.66

Seagen Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Change In Receivables	Get a 7-Day Free Trial															-48.71	-15.16	6.14	-90.27	-45.51

Seagen Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-145 Mil.

Seagen (NAS:SGEN) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Seagen's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	631.555	/	648.65	*	91
=	88.85

2. In Ben Graham's calculation of liquidation value, Seagen's accounts receivable are only considered to be worth 75% of book value:

Seagen's liquidation value for the quarter that ended in Sep. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1236.986	-	1083.84	+	0.75 * 631.555	+	0.5 * 531.188
=	892

Seagen Change In Receivables Related Terms

Thank you for viewing the detailed overview of Seagen's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Seagen (Seagen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seagen Inc (NAS:SGEN) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

21823 - 30th Drive South East, Bothell, WA, USA, 98021

Website

https://www.seagen.com

Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.

Executives

David R Epstein	director, officer: Chief Executive Officer	INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Vaughn B Himes	officer: See Remarks	C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Charles R Romp	officer: EVP, Commercial	21823 30TH DRIVE SE, BOTHELL WA 98021
Roger D Dansey	officer: See Remarks	21823 30TH DRIVE SE, BOTHELL WA 98021
Jean I Liu	officer: GC & EVP, Legal Affairs	21823 30TH DRIVE SE, BOTHELL WA 98021
Todd E Simpson	officer: Chief Financial Officer
Daniel G Welch	director	4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
David W Gryska	director	749 N MARY AVE, SUNNYVALE CA 94085
Sandra M Swain	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Ted W Love	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Clay B Siegall	director, officer: President and CEO	21823 30TH DR SE, BOTHELL WA 98021
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014